Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok

TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) — Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro Technics in Scarborough, Ontario to perform preclinical toxicology and pharmacology studies for Metablok, the Company’s drug candidate for treating inflammation, cancer metastasis and sepsis.

Read more

Arch Biopartners Initiates Manufacturing Process for Metablok

TORONTO, ONTARIO–(Marketwired – Oct. 10, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged CSBio in Menlo Park, California, to begin the manufacturing process for Metablok, the Company’s drug candidate for treating inflammation, cancer metastasis and sepsis.

Read more

Arch Biopartners Increases Non-Brokered Private Placement Financing

TORONTO, ONTARIO–(Marketwired – Sept. 12, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced today it has increased the size of the non-brokered private placement the Company previously announced in a press release August 10, 2017, from $155,000 to $200,000 (the “Offering”).

Read more

Arch Biopartners Provides Update on GMP Manufacturing of AB569

TORONTO, ONTARIO–(Marketwired – July 27, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) today provided an update on the progress of the good manufacturing practice (GMP) production campaign for AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients.

Read more

Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing

TORONTO, ONTARIO–(Marketwired – July 24, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announced today it has retained Mackie Research Capital Corporation (“Mackie Research”) to provide market-making services to the Company in compliance with, and subject to, the policies, guidelines and approval of the TSX Venture Exchange and other applicable legislation.

Read more

Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services

TORONTO, ONTARIO–(Marketwired – May 4, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced Dalton Pharma Services (Dalton) has launched the good manufacturing practice (GMP) campaign for AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.

Read more

Grant of Options to Directors, Officers and Scientists

TORONTO, ONTARIO–(Marketwired – April 18, 2017) – Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announces the Company’s board has granted a total of 2,100,000 stock options to its directors, officers and certain scientists pursuant to the Company’s stock option plan and the requirements of the TSX Venture Exchange (TSXV).

Read more

Arch Biopartners’ Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial

TORONTO, ONTARIO–(Marketwired – April 13, 2017) – Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that the Cincinnati Veterans Affairs Medical Center (CVAMC) will conduct an investigator initiated Phase I human trial to evaluate the safety and pharmacokinetic profile of AB569, the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.

Read more